CK156（Cat No.:I043496）is a selective inhibitor of the enzyme cyclin-dependent kinase 4/6 (CDK4/6), which plays a key role in regulating the cell cycle, particularly in the transition from the G1 to S phase. By inhibiting CDK4/6, CK156 effectively halts uncontrolled cell division, making it a promising therapeutic candidate for the treatment of various cancers, including breast cancer and other CDK4/6-dependent malignancies. This targeted approach can slow tumor growth and enhance the efficacy of existing cancer therapies, offering a potential strategy for managing cancers with dysregulated cell cycle progression.